VGXI Launches New Website, Receives QP Declaration for its Texas Manufacturing Facility

Share Article

VGXI announced today the launch of its newly redesigned website and the receipt of QP declaration for its Texas manufacturing facility.

VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today the launch of its newly redesigned website which can be found at http://www.vgxii.com. The new site highlights the important work VGXI’s clients are doing to prevent and treat infectious diseases and cancer.

According to Dorothy Peterson, VP Operations, “Our clients are developing technologies that have the potential to help millions of people. It is our privilege to support them in this noble endeavor.”

The new site provides visitors with a more user-friendly interface on which to learn about the Company’s services and core technology. It also has a new, streamlined navigation layout that allows for easy access to a broad range of information and resources.

Also, on July 27, 2012, VGXI announced that they have received a Qualified Persons (“QP”) declaration certifying that VGXI’s facility in The Woodlands, Texas is compliant with the standards of Good Manufacturing Practices (GMP) equivalent to those applied in the EU. VGXI sought a QP declaration at the request of a client planning a clinical trial in Europe. The DNA product manufactured at VGXI for this client may now be used in their planned trial in the EU.

Between January 2012 and July 2012, VGXI has hosted 6 Quality System audits, representing 5 different clients. The audits have encompassed the regulations for U.S., Europe and Australia’s Pesticides and Veterinary Medicines Authority. VGXI successfully passed all QA audits allowing their clients to proceed to manufacture product for use in clinical trials in the U.S., Europe and Australia.

Finally, in addition to existing GMP Plasmid manufacturing services for Phase I and II clinical studies, VGXI has recently launched a new plasmid manufacturing service called “HD Production”. Plasmids manufactured using this cost-effective service are highly documented and suitable for use as raw materials in applications such as GMP viral vector manufacturing and toxicology studies.

About VGXI, Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for client clinical studies in the US and Europe, and its GMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible GMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical data set.

Cautionary Factors That May Affect Future Results
Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements do not relate strictly to historical or current facts and can therefore be identified as such. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Media Contact:
David Colvin
dcolvin(at)vgxii(dot)com
2700 Research Forest Dr.
Suite 180
The Woodlands, TX 77381
USA
Ph: 281-296-7300

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Colvin

281-296-7300
Email >
Visit website